SYNTAX Score

SYNTAX Score
Name	SYNTAX Score
Purpose	Anatomical complexity grading of coronary artery disease
Introduced	2000s

SYNTAX Score The SYNTAX Score is an angiographic tool used to quantify the anatomical complexity of coronary artery disease for treatment planning and prognosis. It integrates lesion characteristics to guide decision-making among percutaneous coronary intervention, coronary artery bypass grafting, and conservative strategies in patients with complex coronary anatomy. Prominent cardiovascular centers, trials, and guideline committees have incorporated the score into comparative effectiveness research and practice algorithms.

Introduction

The SYNTAX Score was developed to provide an objective anatomical metric linking coronary lesion morphology with outcomes observed in randomized trials and registries such as SYNTAX trial, FREEDOM trial, EXCEL trial, CABG-related cohorts, and multicenter studies led by institutions like Cleveland Clinic, Mayo Clinic, and Mount Sinai Hospital. It interfaces with professional societies including the European Society of Cardiology, the American College of Cardiology, and the American Heart Association for recommendations and heart team discussions involving specialists from Johns Hopkins Hospital, Brigham and Women's Hospital, and Royal Brompton Hospital. The score informed landmark comparative analyses performed by investigators affiliated with Columbia University, Stanford University, Imperial College London, and University of Oxford.

History and Development

The concept originated in response to variability highlighted by early interventional pioneers at centers such as National Heart, Lung, and Blood Institute, Thoraxcenter, and teams collaborating across Harvard Medical School and University of Toronto. Initial methodological framing drew on angiographic classification work from groups at Stanford University Medical Center, Utrecht University, and Cleveland Clinic Foundation. Building on trial design expertise from PARTNER trial investigators and registry methodology from SCAAR registry contributors, the score underwent validation in cohorts recruited at Karolinska University Hospital, Asan Medical Center, and Seoul National University Hospital. International consensus and reproducibility studies involved investigators from John Radcliffe Hospital, University of Barcelona, and Mount Sinai School of Medicine.

Calculation and Components

Calculation relies on detailed angiographic assessment of coronary segments originally mapped by anatomical descriptions from textbooks associated with Guy's Hospital, Mayo Clinic School of Medicine, and imaging labs at Massachusetts General Hospital. Lesion features quantified include calcification, bifurcation involvement (noted in work at St Thomas' Hospital), total occlusion, tortuosity, and length—parameters studied by researchers at Imperial College, Icahn School of Medicine at Mount Sinai, and University College London. Trained operators from programs at Columbia University Irving Medical Center, Vanderbilt University Medical Center, and University of Michigan apply scoring rules that allocate points per lesion and sum to yield an aggregate reflecting disease complexity; reproducibility was examined in collaborations with Duke University Medical Center and Johns Hopkins University School of Medicine.

Clinical Applications and Indications

Clinicians at centers including Cleveland Clinic Foundation, Mount Sinai Hospital, Guy's and St Thomas' NHS Foundation Trust, and Royal Brisbane Hospital use the score in multidisciplinary heart team meetings alongside specialists from Texas Heart Institute, Hospital Clínic de Barcelona, and Edmonton Cardiac Centre. It serves to stratify patients considered for coronary artery bypass grafting at institutions like Toronto General Hospital or percutaneous coronary intervention performed at Christie Hospital. Guideline panels from European Society of Cardiology, American College of Cardiology, and Society for Cardiovascular Angiography and Interventions cite the score in recommendations for multi-vessel and left main disease management, informed by analyses from Brigham and Women's Hospital and University of Sydney investigators.

Prognostic Value and Outcomes

Prognostic studies involving populations from SYNTAX trial, FREEDOM trial, EXCEL trial, and registries such as SCAAR and NCDR demonstrated correlations between higher scores and increased rates of major adverse cardiovascular events observed in cohorts at Cleveland Clinic, Johns Hopkins Hospital, and Massachusetts General Hospital. Long-term outcome analyses by teams at Duke University, Stanford University, and Oxford University Hospitals linked elevated scores to mortality, repeat revascularization, and myocardial infarction, informing risk-adjusted comparisons across surgical and percutaneous strategies in settings like Royal Victoria Hospital and University Hospital Zurich.

Limitations and Criticisms

Critiques articulated by investigators at Yale School of Medicine, University of Toronto, and Imperial College London highlight reliance on angiography without physiologic indices emphasized by groups at Vanderbilt University and Mayo Clinic. Concerns were raised in methodological reviews from Johns Hopkins University, Karolinska Institutet, and University of Edinburgh about interobserver variability and applicability to contemporary device technologies studied at Cleveland Clinic and St Luke's International Hospital. Comparative work from Mount Sinai, McMaster University, and Monash University argued for integration with fractional flow reserve research from University of Bern and imaging modalities advanced at Mayo Clinic.

Variants and Related Scoring Systems

Related tools and adaptations were proposed in studies from Duke University Medical Center, University of Barcelona, Seoul National University Hospital, and Asan Medical Center, including the development of the Residual SYNTAX framework and hybrid indices combining physiological metrics researched at Stanford University and Imperial College London. Other coronary complexity scores encountered in literature include the Gensini score studied at University of Milan, the TIMI risk score developed with contributors from Brigham and Women's Hospital, and the COURAGE trial–influenced risk stratification approaches from Vanderbilt University Medical Center and Baylor College of Medicine.

Category:Cardiology